
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo is used to treat the involuntary movements of Huntington's disease and tardive dyskinesia (TD). Includes Austedo side effects, dosage, uses, interactions, and more
Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine ...
See Prescribing Information, including Boxed Warning. Find information for healthcare professionals about once-daily AUSTEDO XR.
Tardive Dyskinesia Treatment | AUSTEDO XR® (deutetrabenazine)
See Important Safety Information, including Boxed Warning. How AUSTEDO XR® (deutetrabenazine) extended-release tablets may help.
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Dec 2, 2025 · AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting …
Austedo: Regaining Control Over Uncontrolled Movements in ...
Jul 16, 2024 · Tardive dyskinesia (TD) is a disorder that can cause repetitive movements such as twitching, shaking, or jerking in the arms, legs, face (including eyes and mouth), and torso. …
Austedo (Deutetrabenazine): Uses & Side Effects
Austedo is a brand of deutetrabenazine. This medication treats involuntary movements caused by tardive dyskinesia or Huntington's disease.
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia ...
Nov 12, 2025 · New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.
AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
List of 21 Tardive Dyskinesia Medications Compared - Drugs.com
Mar 5, 2024 · Compare risks and benefits of common medications used for Tardive Dyskinesia. Find the most popular drugs, view ratings and user reviews.
Deutetrabenazine Tablets Improve Tardive Dyskinesia Symptoms
Oct 22, 2025 · Teva Pharmaceuticals announced new data from the ongoing, real-world IMPACT-TD Registry, which demonstrates that treatment with deutetrabenazine tablets or …